[Effects of SARS-CoV-2 Infection on Symptoms and Therapy of Inflammatory Bowel Disease]. / Auswirkungen einer SARS-CoV-2-Infektion auf Symptomatik und Therapie chronisch-entzündlicher Darmerkrankungen.
Z Gastroenterol
; 59(11): 1189-1196, 2021 Nov.
Article
in German
| MEDLINE | ID: covidwho-1506904
ABSTRACT
INTRODUCTION:
The influence of a SARS-CoV-2 infection on inflammatory bowel disease (IBD) has not yet been well characterized and it is unclear whether this requires an adaptation of the immunosuppressive therapy.METHODS:
A national register was established for the retrospective documentation of clinical parameters and changes in immunosuppressive therapy in SARS-CoV-2 infected IBD patients.RESULTS:
In total, only 3 of 185 IBD patients (1.6â%) were tested for SARS-CoV-2 infection because of abdominal symptoms. In the course of COVID-19 disease, 43.5â% developed diarrhea, abdominal pain or hematochezia (risk of hospitalization with vs. without abdominal symptoms 20.0â% vs. 10.6â%, pâ<â0.01). With active IBD at the time of SARS-CoV-2 detection, there was an increased risk of hospitalization (remission 11.2â%, active IBD 23.3â% pâ<â0.05). IBD-specific therapy remained unchanged in 115 patients (71.4â%); the most common change was an interruption of systemic therapy (16.2â%).DISCUSSION:
New abdominal symptoms often appeared in SARS-CoV-2 infected IBD patients. However, these only rarely led to SARS-CoV-2 testing. A high IBD activity at the time of SARS-CoV-2 detection was associated with an increased risk of hospitalization.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Inflammatory Bowel Diseases
/
COVID-19
Type of study:
Diagnostic study
/
Experimental Studies
/
Observational study
/
Prognostic study
Topics:
Long Covid
Limits:
Humans
Language:
German
Journal:
Z Gastroenterol
Year:
2021
Document Type:
Article
Affiliation country:
A-1508-6734
Similar
MEDLINE
...
LILACS
LIS